Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

3.32EUR
16 Nov 2017
Change (% chg)

€0.06 (+1.81%)
Prev Close
€3.26
Open
€3.32
Day's High
€3.32
Day's Low
€3.32
Volume
0
Avg. Vol
11,967
52-wk High
€4.87
52-wk Low
€3.01

Chart for

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and... (more)

Overall

Beta: 0.01
Market Cap(Mil.): €126.77
Shares Outstanding(Mil.): 38.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Biofrontera adjusts revenues and earnings forecast for FY 2017

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA ADJUSTS REVENUES AND EARNINGS FORECAST FOR THE FINANCIAL YEAR 2017

Nov 14 2017

BRIEF-Biofrontera: CMS issues new reimbursement codes for Ameluz

* PTA-NEWS: BIOFRONTERA AG: CMS ISSUES NEW REIMBURSEMENT CODES FOR AMELUZ® AND FOR PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 10 2017

BRIEF-Biofrontera achieves strong U.S. sales performance of Ameluz in first year

* PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA ACHIEVES STRONG U.S. SALES PERFORMANCE OF AMELUZ® IN FIRST YEAR OF COMMERCIALIZATION

Oct 18 2017

BRIEF-Biofrontera: Ameluz and BF-RhodoLED listed on U.S. VA Federal Supply Schedule

* PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA'S AMELUZ® AND BF-RHODOLED® LISTED ON THE U.S. VA FEDERAL SUPPLY SCHEDULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 09 2017

BRIEF-Biofrontera H1 net loss at 8.1 million euros

* ‍SALES INCREASED BY 193% TO EUR 5.0 MILLION IN H1 2017, COMPARED TO EUR 1.7 MILLION IN SAME PERIOD 2016.​

Aug 31 2017

BRIEF-Biofrontera strengthens its U.S. sales support services

* ‍COMPLETED EXPANSION OF ITS U.S. UNIT TO STRENGTHEN COMMERCIAL OPERATIONS AND INTERNAL SALES SUPPORT SERVICES TO SUPPORT INCREASING MOMENTUM FOR AMELUZ® IN U.S. MARKET​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 09 2017

BRIEF-Biofrontera: warrant bond 2009/2017 will be repaid early

* ‍REPAYMENT IS CURRENTLY FORESEEN FOR 3 AUGUST 2017​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 28 2017

BRIEF-Biofrontera files label extension for Ameluz in EU

* FILES LABEL EXTENSION FOR AMELUZ IN EU TO INCLUDE TREATMENT WITH DAYLIGHT-PDT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 12 2017

Earnings vs. Estimates